Multiplexed Biomarkers for staging Alzheimer???s Disease

用于分期阿尔茨海默病的多重生物标志物

• 批准号: 8371247
• 负责人: KUMAR SUBRAMANIAN
• 金额: $ 17.08万
• 依托单位: PHOENIX BIOSYSTEM, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8371247
• 关键词: Alzheimer' s Disease; Amendment; Antibodies; Archives; Award; Biological Assay; Biological Markers; Biosensor; Buffers; Cerebrospinal Fluid; Chromogranin A; Clinical; Clinical Trials; Clinical Trials Design; Cognitive; Complex; Consultations; Dementia; Detection; Diagnosis; Diagnostic; Discrimination; Disease; Disease Marker; Enzyme-Linked Immunosorbent Assay; Fluorescence; Goals; Immunoassay; Impaired cognition; Institutional Review Boards; Label; Laboratories; Laboratory Research; Lead; Measures; Microfluidics; Milk; Neurology; Noise; Normalcy; Optics; Pathology; Patient Care; Performance; Phase; Plasma; Preparation; Prevalence; Proteins; Proteomics; Reagent; Research; Risk; Role; Sampling; Schedule; Scheme; Sensitivity and Specificity; Serum; Signal Transduction; Staging; System; Technology; Testing; Time; Universities; Validation; Washington; Whole Blood; Work; aminoacyl-histidine dipeptidase; assay development; base; cost effective; cross reactivity; diagnostic accuracy; experience; improved; medical attention; medical schools; novel; nucleic acid detection; professor; prognostic; public health priorities; tau Proteins; tool

DESCRIPTION (provided by applicant): With the growing prevalence of AD, the ability to accurately and reliably diagnose AD in its earliest stages has become a public health priority. Clinicopathological studies suggest that AD pathology begins 10-15 years before the resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and predict dementia onset would, therefore, be invaluable for patient care and efficient clinical trial design. Multiplex immunoassay platforms such as the one we are proposing to develop, allow for the simultaneous quantitation of many analytes, and by adhering to clinical laboratory improvement amendments (CLIA) standards, are amenable for clinical trial work. Our multiplexed, low sample volume, ultra-sensitive assay open up the opportunity to study a wide range of potential pathogenic markers in CSF, which could lead to very informative diagnostic tools for the disease. PUBLIC HEALTH RELEVANCE: The overall goal (PHASE I and II) of the proposed collaborative research is to develop a cost effective, easy-to-use, fluorescence optics based high sensitive assay platform for measuring novel cerebrospinal fluid (CSF) biomarkers associated with Alzheimer's Disease (AD).

描述（由申请人提供）：随着AD的日益流行，在其最早阶段准确可靠地诊断AD的能力已成为公共卫生的优先事项。临床病理学研究表明，AD病理学在所导致的认知障碍引起医学关注之前10-15年开始。因此，可以在早期阶段检测AD病理并预测痴呆发作的生物标志物对于患者护理和有效的临床试验设计将是非常宝贵的。多重免疫分析平台，如我们建议开发的平台，允许同时定量许多分析物，并遵守临床实验室改进修正案（CLIA）标准，适合临床试验工作。我们的多重、低样本量、超灵敏的检测方法为研究CSF中广泛的潜在致病性标志物提供了机会，这可能会为该疾病提供非常丰富的诊断工具。 公共卫生关系：拟议的合作研究的总体目标（第一阶段和第二阶段）是开发一种具有成本效益，易于使用，基于荧光光学的高灵敏度测定平台，用于测量与阿尔茨海默病（AD）相关的新型脑脊液（CSF）生物标志物。